FDA green-lights 23andMe to sell test for 3 mutations of breast cancer gene
The FDA on Tuesday will allow genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.
0 comments:
Post a Comment